If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 1 - 8 of 8

An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses

Objective
IIT-GEORGE-I-PREDICT
Protocol No
IIT-GEORGE-I-PREDICT
Categories
Cancer, Colorectal, Gynecologic Cancers, Esophagus, Other Urologic, Head and Neck Cancers, Early Phase/Multiple Disease Site Cancers, Esophagus, Skin Cancers, Stomach, Prostate and Urologic Cancers, Pancreas/Liver, Breast Cancers, Other Gastrointestinal, Sarcoma, Gastrointestinal Cancers, Lung, Thoracic Cancers

A Multicenter, Randomized, Open-Label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients with Cancer Associated VTE

Objective
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE (ASTER)
Protocol No
ANTHOS-ANT-007
Categories
Cancer, Eye/Orbital Cancers, Skin Cancers, Cervix, Lip, Oral Cavity and Pharynx, Sarcoma, Other Gastrointestinal, Other Blood Related, Pancreas/Liver, Uterine, Other Respiratory, Gynecologic Cancers, Brain and Spine Cancers, Bladder, Lung, Head and Neck Cancers, Leukemia, Prostate, Esophagus, Thoracic Cancers, Colorectal, Hematologic/Blood Related Cancers, Gastrointestinal Cancers, Kidney, Endocrine Cancers, Prostate and Urologic Cancers, Multiple Myeloma, Breast Cancers

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors

Objective
To assess the safety, tolerability, dose-limiting toxicities (DLTs), and determine the maximum tolerated dose of INBRX-106 as a single agent administered as an intravenous infusion and in combination with pembrolizumab.
Protocol No
INHIBRX-PH1-INBRX-106
Categories
Cancer, Other Gastrointestinal, Gynecologic Cancers, Kidney, Melanoma, Skin, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gastrointestinal Cancers, Thoracic Cancers, Early Phase/Multiple Disease Site Cancers

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion

Objective
A Phase 1/2 Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Protocol No
MIRATI-1719-001
Categories
Cancer, Other Skin, Thoracic Cancers, Gynecologic Cancers, Other Gastrointestinal, Early Phase/Multiple Disease Site Cancers, Lip, Oral Cavity and Pharynx, Melanoma, Skin, Esophagus, Bladder, Pancreas/Liver, Prostate, Skin Cancers, Kidney, Prostate and Urologic Cancers, Head and Neck Cancers, Colorectal, Gastrointestinal Cancers, Sarcoma, Breast Cancers

Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases

Objective
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Protocol No
NRG-BN013
Categories
Cancer, Other Skin, Bladder, Colorectal, Cervix, Other Gynecologic, Breast Cancers, Esophagus, Prostate, Larynx, Other Gastrointestinal, Esophagus, Gynecologic Cancers, Other Respiratory, Melanoma, Skin, Prostate and Urologic Cancers, Pancreas/Liver, Eye/Orbital Cancers, Thoracic Cancers, Lip, Oral Cavity and Pharynx, Head and Neck Cancers, Gastrointestinal Cancers, Endocrine Cancers, Skin Cancers, Brain and Spine Cancers

High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)

Objective
A Phase II study of Re-Irradiation Utilizing DIR and OAR Dose Calculations with Organ Specific Toxicity Analysis
Protocol No
IIT-GORE-REDIRICT
Categories
Cancer, Lip, Oral Cavity and Pharynx, Cervix, Melanoma, Skin, Skin Cancers, Prostate and Urologic Cancers, Breast Cancers, Other Gastrointestinal, Gynecologic Cancers, Thoracic Cancers, Pancreas/Liver, Esophagus, Colorectal, Endocrine Cancers, Gastrointestinal Cancers, Sarcoma, Larynx, Brain and Spine Cancers, Head and Neck Cancers